Eton Pharmaceuticals, Inc. — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019. Unaudited results; dollar amounts below are in thousands except per-share data.
Business context
Eton is a specialty pharmaceutical company developing and commercializing prescription products, primarily through the FDA’s 505(b)(2) pathway. The company reported limited revenue and expects significant revenue to depend on development progress and FDA approvals. Management said four product candidates had been submitted to the FDA for review.
Financial results and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $500 | $0 |
| Research and development expense | $1,439 | $1,707 | $7,904 | $2,981 |
| General and administrative expense | $1,910 | $990 | $3,499 | $2,680 |
| Net loss | $(3,249) | $(3,082) | $(10,659) | $(6,100) |
| Net loss per share, basic and diluted | $(0.18) | $(0.79) | $(0.61) | $(1.80) |
- Margins: Not meaningful for Q2, which had no revenue; first-half revenue was a one-time product-rights payment rather than reported product sales.
- Cash flow: First-half operating cash use was $10,963, investing cash use was $1,030, and financing cash provided was $205. Cash declined by $11,788 to $14,947.
- Balance sheet at June 30: Cash and cash equivalents of $14,947; current assets of $16,755; current liabilities of $1,459; total assets of $18,244; total liabilities of $1,545; and accumulated deficit of $56,527.
- Debt and liquidity: No borrowings are reported on the balance sheet. Lease liabilities totaled $213. Management believed available cash would fund operating and capital needs for at least 12 months from issuance, based on current assumptions, including spending management; it cautioned cash could be used sooner and additional financing might be needed.
Changes versus prior comparable periods
- Q2 operating expenses rose to $3,349 from $2,697, primarily because G&A increased with headcount, public-company costs, marketing planning, and distribution setup. Lower DS-300 testing and EM-100 clinical-study expenses partly offset higher indirect costs.
- First-half R&D expense rose substantially, reflecting $3,350 in signing milestones for ET-202, ET-203, and ET-104, a $1,500 DS-200 milestone, and $889 more indirect expense from personnel and the laboratory; lower EM-100 clinical costs partly offset the increases.
- First-half net loss increased to $10,659 from $6,100, and operating cash use increased to $10,963 from $4,078. The prior-year periods included warrant fair-value expense ($413 in Q2 and $496 for the first half); there was no such expense in 2019.
- Weighted-average shares increased, principally reflecting the November 2018 IPO and conversion of preferred stock. Consequently, reported loss per share improved from the prior-year periods despite higher absolute net losses.
Outlook, risks, and unusual items
- The $500 first-half revenue came from selling EM-100 product rights to Bausch. The agreement provides for up to $2,500 in commercial milestones upon first commercial sale and royalties on U.S. net sales for 10 years from first commercial sale. No royalty revenue had been recognized to date.
- In May 2019, Eton sold CT-100 rights to Harrow, a related party, for development and commercial milestones plus low-single-digit royalties under specified terms. The filing does not provide a clear value for potential proceeds.
- Several product agreements require upfront, regulatory, or commercial milestone payments and share future profits or royalties. For example, ET-202 and ET-203 required upfront payments of $2,000 and $1,000, respectively; the filing reports these as R&D signing fees. Eton also paid $1,500 for a DS-200 NDA-submission milestone.
- The ET-105 agreement was signed in June; a $2,000 payment followed FDA acceptance for review in August 2019, after the quarter. Further approval and patent milestones, royalties, and commercial milestones may apply.
- Development, manufacturing, and regulatory execution; FDA review and approval timing; competition; and access to additional capital are material uncertainties. If development or approval is delayed and financing is unavailable, Eton said it may need to scale back or discontinue operations.
- The company disclosed related-party arrangements involving Harrow and entities affiliated with its CEO, including product-rights, development, milestone, and profit-sharing arrangements. It reported no pending or threatened litigation expected to have a material impact and no material changes to risk factors from its 2018 Form 10-K.
- Management concluded disclosure controls and procedures were effective for the period; it reported no material change in internal control over financial reporting.
Key facts for investors to verify
- Current FDA status, approval timelines, and remaining development requirements for the four submitted candidates and other pipeline products.
- Cash runway against actual spending, future milestone obligations, and the assumptions supporting management’s stated 12-month liquidity estimate.
- Terms, timing, and likelihood of EM-100 and CT-100 milestones and royalties, including the effects of related-party agreements.
- Whether product launches and commercial economics can generate meaningful revenue after licensing costs, royalties, and profit-sharing arrangements.
- Potential dilution and financing needs, including outstanding options and warrants; common shares outstanding were 17,763,045 at July 31, 2019.